Zetomipzomib - Kezar Life Sciences
Alternative Names: KZR-616Latest Information Update: 26 May 2025
At a glance
- Originator Onyx Pharmaceuticals
- Developer Everest Medicines; Kezar Life Sciences
- Class Anti-inflammatories; Antianaemics; Antirheumatics; Cyclopentanes; Hepatoprotectants; Morpholines; Small molecules; Urologics
- Mechanism of Action Proteasome inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Autoimmune hepatitis; Dermatomyositis; Lupus nephritis; Polymyositis; Systemic lupus erythematosus
- Preclinical Haemophagocytic lymphohistiocytosis
- No development reported Autoimmune disorders
Most Recent Events
- 13 May 2025 Efficacy data from a phase IIb PALIZADE trial in Lupus nephritis released by Kezar Life Sciences
- 13 May 2025 Efficay and adverse events data from a phase IIa PORTOLA trial in Autoimmune hepatitis released by Kezar Life Sciences
- 30 Apr 2025 Kezar Life Sciences completes a phase-II PORTOLA trial in Autoimmune hepatitis in USA (SC) (NCT05569759)